Activated protein C (APC) is inhibited primarily by the serine protease inhibitors \( \alpha_1 \)-antitrypsin (\( \alpha_1 \)AT) [1], protein C inhibitor (PCI) [1], and \( \alpha_2 \)-macroglobulin [2,3]. We recently demonstrated in a large French–Canadian kindred that over half of the variance in the APC–\( \alpha_1 \)AT complex and APC–PCI complex plasma concentrations could be attributed to genetic influences [4]. As this thrombophilic kindred has protein C deficiency and these complexes reflect the level of APC, we used variance component linkage analysis to identify quantitative trait loci that might explain the inherited component of the variance in APC–\( \alpha_1 \)AT and APC–PCI plasma concentrations.

The study subjects were members of the French–Canadian kindred. The ascertainment, evaluation, and blood collection of all family members were described previously [5], as well as the methods for measuring plasma concentrations of APC–\( \alpha_1 \)AT complex, APC–PCI complex, protein C activity, and prothrombin activation fragment 1.2 (FI.2) [4]. \( \alpha_1 \)AT plasma concentrations were measured by the Beckman–Coulter Image system, and PCI plasma concentrations were measured using a kit from Enzyme Research Laboratories (South Bend, IN, USA). This study was approved by the Human Experimentation Committee of the University of Vermont College of Medicine, Burlington, Vermont, USA. All participating subjects gave informed consent. For the current analysis, we included individuals for whom we had plasma concentrations

Correspondence: E. G. Bovill, Department of Pathology, University of Vermont, Given Building #E208, 89 Beaumont Avenue, Burlington VT 05405, USA.

Tel.: +1 802 656 0359; fax: +1 802 656 8892; e-mail: edwin.bovill@uvm.edu

Received 1 December 2005, accepted 6 December 2005

© 2006 International Society on Thrombosis and Haemostasis
of APC–z1AT and APC–PCI complex, and genotyping data (n = 148). We excluded individuals on coumarin derivatives (n = 9), women who were pregnant at the time of the blood draw (n = 2), and women for whom we had no information on the use of female hormones (n = 2). Genotyping was performed with 375 autosomal markers as described by Hasstedt et al. [6]. The probability of identity by descent (IBD) was estimated using the linkage analysis package Loki [7]. Additional markers for fine mapping were genotyped using an ABI310 or 3100 at the Vermont Cancer Center DNA analysis facility, and selected markers were run by Decode Genetics Inc. (Reykjavik, Iceland). Using Sequential Oligogenic Linkage Analysis Routines (SOLAR) [8] version 2.1.4, we performed variance component linkage analysis. All (transformed) levels were assumed to be distributed as a multivariate normal density. The parameters for heritability ($h^2$), household effect ($c^2$), and heritability that was contributed to a specific genomic location ($q^2$) as well as the effects of the covariates were estimated simultaneously using maximum likelihood analysis. LOD scores were computed as the log10 likelihood for linkage was observed for protein C, F1.2, and heritability that was contributed to a specific genomic location ($q^2$), household effect ($c^2$), and heritability that was contributed to a specific genomic location ($q^2$) estimated to $q^2 = 0$. As proposed by Lander and Kruglyak [9], we defined significant linkage as statistical evidence expected to occur 0.05 times in a whole genome scan (probability 5%; LOD score $\geq 3.3$) and suggestive linkage as statistical evidence that would be expected to occur one time in a random in a whole genome scan (LOD score between 1.9–3.3). The 95% confidence interval (CI) was determined by the points on the curve defined by dropping the lod score by one unit.

A total of 135 subjects were included in the analysis. Subjects were from 92 households with a mean of 1.4 individuals per household (range 1–4 individuals). The mean age at the blood draw was 28 years (range 1–75 years), 75 participants were women (56%), 28 (21%) carried the protein C 3363C insertion, 28 (21%) carried the prothrombin G20210A mutation (one was homozygous) and eight (6%) had a history of confirmed venous thrombosis. Variance component linkage analysis on plasma concentrations of APC–z1AT complex revealed LOD scores above one for chromosomes 13, 14, and 19 (adding age, sex, and use of female hormones as covariates to the model). LOD scores suggestive of linkage were found on chromosome 19p13.2 (LOD score 3.1 at 35 cM; 95% CI 25–40 cM, nearest marker D19S866) and on chromosome 13q14 (LOD score 2.0 at 56 cM; 95% CI 49–68 cM, nearest marker D13S800) (Table 1). However, adding markers in the area under the peak at chromosome 19 decreased the LOD score to 2.2 (Table 1). Eliminating levels of individuals with a confirmed history of thrombosis decreased the LOD score on chromosome 13 to 1.6 and on chromosome 19 to 1.9 (Table 1). Inclusion of protein C status as a covariate in the model did not alter the lod scores (Table 1). For plasma concentrations of APC–PCI complex LOD scores above one were found on chromosomes four and 11 (adding age, sex, and use of female hormones as covariates in the model). The highest LOD score was found on chromosome 11q25 (LOD score 2.2 at 141 cM; 95% CI 126–147, nearest marker D11S1304) (Table 1). The LOD score increased to 2.9 after eliminating the levels of individuals with a confirmed history of venous thrombosis (Table 1). Adding markers in the area under the peak decreased the LOD score on chromosome 11 to 2.3 (Table 1). The LOD score remained 2.3 after removal of the effect of APC–PCI complex. The LOD score remained 2.3 after removal of the effect of protein C status in the model (Table 1). No evidence for linkage was observed for protein C, F1.2, z1AT, PCI and APC–PCI–a1AT complexes, which reflect the activity of the protein C system. In the regions showing suggestive linkage evidence, no specific candidate genes were identified. Thus, it appears that yet-to-be-determined novel genes may play a role in modulating APC activity. The only other report of quantitative trait loci linked to the variance in plasma concentrations of APC–PCI and APC–z1AT complexes, which reflect the activity of the protein C system was that of Soria et al. [10], which reported a locus on chromosome 18 that influences variation in the APC resistance phenotype.

### Acknowledgements

We would like to thank J. E. Vailiere, G. L. Long, and P. W. Callas for their contribution to the study. This study was supported by an NHLBI grant PHS HL46703 and a Transatlantic Network for Excellence in Cardiovascular Research grant from Fondation Leducq, Paris, France.
We read with interest the paper by Imberti et al. [1] and agree with their views regarding the need for documentation of the length of implantation time for retrievable vena cava filters. The authors report an average implantation time of 123 days with a maximum of 345 days.

In our own recent experience (21 filters implanted and only 12 already extracted at the moment), the longest implantation time was 485 days in a 35-year-old man in which filter implantation was indicated for proximal deep vein thrombosis in a context of acute alcoholic pancreatitis with abdominal bleeding. The patient was momentarily lost for follow-up after hospital discharge but came back to our institution 15 months later. Decision to make an attempt at removing the filter was taken despite this long delay because of his poor compliance for any kind of follow-up and the absence of permanent risk factor for thromboembolic disease. Correct position of filter and permeability of vena cava were confirmed by computed tomographic scan prior to the procedure. The filter was easily extracted using the procedure recommended by the manufacturer without any mechanical damage to the venous wall. The examination of the filter revealed only minor clots in the legs. The implantation time in our patient is, to our knowledge, the longest described in the literature [1,2].

As with other authors [3], we believe that the interest of using such temporary filters increases when the expected period of implantation time can be counted in weeks or months rather than in days, and agree that further scientific evidence is needed [4] before such long implantation durations, as in the case we report, should be encouraged. In the mean time, we feel that such individual experience driven by unusual clinical situations should be reported in order to make the information available. A large multicenter register could be the most efficient way for this purpose.